"Designing Growth Strategies is in our DNA"
Arterial thrombosis is a blood clot developed in an artery. Arterial thrombosis can cause heart attack, stroke, transient ischaemic attack (TIA), critical limb ischemia and other complications in the human body. Arterial thrombosis can also be caused due to atrial fibrillation or antiphospholipid syndrome. One of the major cause of arterial thrombosis is attributed to the damaged artery due to a condition called atherosclerosis.
Current treatment for arterial thrombosis includes medication and surgery. The medications prescribed include anticoagulants such as heparin, warfarin, and others. The surgeries performed are coronary angioplasty, coronary artery bypass graft (CABG), carotid endarterectomy and others. In 2018, Portola Pharmaceuticals, Inc., received FDA approval for Andexanet alfa, an antidote for the rivaroxaban and apixaban, given at the time-reversal of anticoagulation due to uncontrolled bleeding.
Research Institutes and pharmaceutical companies are focusing on studying and developing new methods for the treatment of arterial thrombosis. For instance; [18F]GP1, which is being studied by the Asan Foundation, is currently in phase-1 clinical trials for the study of safety, pharmacokinetics, biodistribution, and diagnostic performance of [18F]GP1 PET in thromboembolism.
To know how our report can help streamline your business, Speak to Analyst
Currently, more than 50% of the pipeline candidates for arterial thrombosis are in phase 3 and phase 4 stage. Majority of the studies have been sponsored by research institutes.
The report on ‘Arterial Thrombosis – Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for arterial thrombosis. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for Arterial Thrombosis.
The report on ‘Arterial Thrombosis – Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.